Cargando…

Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer

BACKGROUND: The incidence and mortality of early-onset colorectal cancer (EOCRC; < 50 years old) is increasing worldwide, with a high recurrence rate. The inherent heterogeneity of EOCRC makes its treatment challenging. Hence, to further understand the biology and reveal the molecular mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jia, Zhao, Yuting, Yuan, Rongqiang, Wang, Yongtong, Wang, Shiyi, Chang, Zhiqiang, Zhao, Wenyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658991/
https://www.ncbi.nlm.nih.gov/pubmed/37986009
http://dx.doi.org/10.1186/s40001-023-01491-y
_version_ 1785148271270821888
author Yang, Jia
Zhao, Yuting
Yuan, Rongqiang
Wang, Yongtong
Wang, Shiyi
Chang, Zhiqiang
Zhao, Wenyuan
author_facet Yang, Jia
Zhao, Yuting
Yuan, Rongqiang
Wang, Yongtong
Wang, Shiyi
Chang, Zhiqiang
Zhao, Wenyuan
author_sort Yang, Jia
collection PubMed
description BACKGROUND: The incidence and mortality of early-onset colorectal cancer (EOCRC; < 50 years old) is increasing worldwide, with a high recurrence rate. The inherent heterogeneity of EOCRC makes its treatment challenging. Hence, to further understand the biology and reveal the molecular mechanisms of EOCRC, a recurrence risk signature is needed to guide clinical management. METHODS: Based on the relative expression orderings (REOs) of genes in each sample, a prognostic signature was developed and validated utilizing multiple independent datasets. The underlying molecular mechanisms between distinct prognostic groups were explored via integrative analysis of multi-omics data. RESULTS: The prognostic signature consisting of 6 gene pairs (6-GPS) could predict the recurrence risk for EOCRC at the individual level. High-risk EOCRC classified by 6-GPS showed a poor prognosis but a good response to adjuvant chemotherapy. Moreover, high-risk EOCRC was characterized by epithelial-mesenchymal transition (EMT) and enriched angiogenesis, and had higher mutation burden, immune cell infiltration, and PD-1/PD-L1 expression. Furthermore, we identified four genes associated with relapse-free survival in EOCRC, including SERPINE1, PECAM1, CDH1, and ANXA1. They were consistently differentially expressed at the transcriptome and proteome levels between high-risk and low-risk EOCRCs. They were also involved in regulating cancer progression and immune microenvironment in EOCRC. Notably, the expression of SERPINE1 and ANXA1 positively correlated with M2-like macrophage infiltration. CONCLUSION: Our results indicate that 6-GPS can robustly predict the recurrence risk of EOCRC, and that SERPINE1, PECAM1, CDH1, and ANXA1 may serve as potential therapeutic targets. This study provides valuable information for the precision treatment of EOCRC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01491-y.
format Online
Article
Text
id pubmed-10658991
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106589912023-11-20 Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer Yang, Jia Zhao, Yuting Yuan, Rongqiang Wang, Yongtong Wang, Shiyi Chang, Zhiqiang Zhao, Wenyuan Eur J Med Res Research BACKGROUND: The incidence and mortality of early-onset colorectal cancer (EOCRC; < 50 years old) is increasing worldwide, with a high recurrence rate. The inherent heterogeneity of EOCRC makes its treatment challenging. Hence, to further understand the biology and reveal the molecular mechanisms of EOCRC, a recurrence risk signature is needed to guide clinical management. METHODS: Based on the relative expression orderings (REOs) of genes in each sample, a prognostic signature was developed and validated utilizing multiple independent datasets. The underlying molecular mechanisms between distinct prognostic groups were explored via integrative analysis of multi-omics data. RESULTS: The prognostic signature consisting of 6 gene pairs (6-GPS) could predict the recurrence risk for EOCRC at the individual level. High-risk EOCRC classified by 6-GPS showed a poor prognosis but a good response to adjuvant chemotherapy. Moreover, high-risk EOCRC was characterized by epithelial-mesenchymal transition (EMT) and enriched angiogenesis, and had higher mutation burden, immune cell infiltration, and PD-1/PD-L1 expression. Furthermore, we identified four genes associated with relapse-free survival in EOCRC, including SERPINE1, PECAM1, CDH1, and ANXA1. They were consistently differentially expressed at the transcriptome and proteome levels between high-risk and low-risk EOCRCs. They were also involved in regulating cancer progression and immune microenvironment in EOCRC. Notably, the expression of SERPINE1 and ANXA1 positively correlated with M2-like macrophage infiltration. CONCLUSION: Our results indicate that 6-GPS can robustly predict the recurrence risk of EOCRC, and that SERPINE1, PECAM1, CDH1, and ANXA1 may serve as potential therapeutic targets. This study provides valuable information for the precision treatment of EOCRC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01491-y. BioMed Central 2023-11-20 /pmc/articles/PMC10658991/ /pubmed/37986009 http://dx.doi.org/10.1186/s40001-023-01491-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Jia
Zhao, Yuting
Yuan, Rongqiang
Wang, Yongtong
Wang, Shiyi
Chang, Zhiqiang
Zhao, Wenyuan
Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer
title Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer
title_full Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer
title_fullStr Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer
title_full_unstemmed Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer
title_short Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer
title_sort identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658991/
https://www.ncbi.nlm.nih.gov/pubmed/37986009
http://dx.doi.org/10.1186/s40001-023-01491-y
work_keys_str_mv AT yangjia identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer
AT zhaoyuting identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer
AT yuanrongqiang identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer
AT wangyongtong identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer
AT wangshiyi identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer
AT changzhiqiang identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer
AT zhaowenyuan identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer